Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Top Cited Papers
- 6 July 2016
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (346) , 346ra92
Abstract
Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. We used massively parallel sequencing–based assays to evaluate the ability of ctDNA to detect minimal residual disease in 1046 plasma samples from a prospective cohort of 230 patients with resected stage II colon cancer. In patients not treated with adjuvant chemotherapy, ctDNA was detected postoperatively in 14 of 178 (7.9%) patients, 11 (79%) of whom had recurred at a median follow-up of 27 months; recurrence occurred in only 16 (9.8 %) of 164 patients with negative ctDNA [hazard ratio (HR), 18; 95% confidence interval (CI), 7.9 to 40; P < 0.001]. In patients treated with chemotherapy, the presence of ctDNA after completion of chemotherapy was also associated with an inferior recurrence-free survival (HR, 11; 95% CI, 1.8 to 68; P = 0.001). ctDNA detection after stage II colon cancer resection provides direct evidence of residual disease and identifies patients at very high risk of recurrence.Keywords
Funding Information
- Virginia and D.K. Ludwig Fund for Cancer Research
- Conrad N. Hilton Foundation
- Sol Goldman Sequencing Facility at Johns Hopkins
- NIH (CA57345, R37-CA43460, U01-CA152753, P30-CA006973)
- Victorian Cancer Agency
- Victorian Cancer Agency Clinical Research Fellowship
This publication has 39 references indexed in Scilit:
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon CancerJournal of Clinical Oncology, 2011
- Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic FeaturesJournal of Clinical Oncology, 2011
- Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581Journal of Clinical Oncology, 2011
- Detection and quantification of rare mutations with massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon CancerJournal of Clinical Oncology, 2010
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer SyndromeThe Journal of Molecular Diagnostics, 2008